King Masterone Propioanate

Description

King Masterone Propionate, scientifically known as Drostanolone Propionate, is a synthetic anabolic-androgenic steroid derived from dihydrotestosterone (DHT). The compound features a methyl group at the carbon-2 position. This modification significantly enhances its anabolic strength by protecting it from metabolic breakdown in skeletal muscle tissue. Researchers originally developed this compound for oncology. Specifically, they used it to treat estrogen-receptor-positive breast cancer in women.

Pharmacokinetics and Research Applications

The propionate ester attaches to the 17-beta hydroxyl group and controls the compound’s release time. This esterification makes the steroid less polar and consequently slows absorption from the injection site. Once in the bloodstream, enzymes remove the ester to yield free active drostanolone. The half-life of Drostanolone Propionate is approximately two days after intramuscular injection. Therefore, this fast-acting profile requires frequent administration in research protocols, typically every other day. In contrast, researchers often compare the Propionate ester to the Enanthate version, which offers a slower release and longer duration.

Mechanism of Action and Effects

Drostanolone Propionate binds to the androgen receptor and subsequently triggers genetic transcriptional changes. These changes promote nitrogen, potassium, and phosphorus retention while increasing protein anabolism. Importantly, this compound does not aromatize – it does not convert to estrogen. Instead, it blocks the aromatase enzyme, thereby reducing estrogen levels and preventing water retention. This mechanism gives it anti-estrogenic properties that researchers study in hormonal modulation contexts. Moreover, the compound is approximately five times as potent as natural methyltestosterone in its androgenic effects.

Safety Profile and Side Effects

Research on Drostanolone Propionate reveals several adverse effects. For instance, male subjects may experience impotence and azoospermia, while female subjects face risks of virilization. Other documented effects include acne, abnormal lipid profiles, and potential cardiovascular strain. Additionally, a well-documented case study reported canalicular cholestasis (liver toxicity) in a 19-year-old male following a 56-day regimen that included Drostanolone Propionate. Fortunately, this condition resolved spontaneously after discontinuing the compound. Nevertheless, the compound also suppresses natural testosterone production, making hormone level monitoring essential for any research protocol.

Internal and External Resources

For detailed handling and storage instructions, please see our Product Handling Guide (Internal Link). Similarly, for safety protocols and research guidelines, visit our Research Safety Page (Internal Link). For external reference, the NCATS Inxight Drugs database (drugs.ncats.io) provides authoritative chemical and pharmacological data on Drostanolone Propionate. Furthermore, the NIST Chemistry WebBook (webbook.nist.gov) offers structural and property information for analytical confirmation. Finally, PubMed (pubmed.ncbi.nlm.nih.gov) contains peer-reviewed studies on this compound’s pharmacokinetics and metabolism.